November 6, 2018

Update on trials of EHL Factor IX

The extended half-life (EHL) factors are being introduced with a sometimes bewildering amount of supporting information and advice, not least the ever-growing evidence base of clinical trials. A new review provides a convenient summary of three ongoing trial programmes – BLONG (eftrenonacog alfa, Alprolix), PROLONG-9FP (albutrepenonacog alfa, Idelvion) and PARADIGM (nonacog beta pegol, Refixia) (Ther Adv Hematol 2018;9:335-346). All recruited previously treated children, young people and adults but trials involving previously untreated patients are now underway.